U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H3FN2O2
Molecular Weight 130.0774
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUOROURACIL

SMILES

c1c(c(nc(n1)O)O)F

InChI

InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf

Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
29.5 µM [IC50]
16.0 nM [IC50]
Target ID: CHEMBL613860
43.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-2.42697601E11
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-2.42697601E11
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-2.42697601E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.49 ng/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
278 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.39 ng × h/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
205 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.24 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
FLUOROURACIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
DLT: Ataxia...
Other AEs: Anorexia, Nausea...
Dose limiting toxicities:
Ataxia (grade 3, 4 patients)
Other AEs:
Anorexia (3 patients)
Nausea (severe, 2 patients)
Vomiting (2 patients)
Stomatitis (severe, 1 patient)
Diarrhea (3 patients)
Weakness (1 patient)
Hair loss (1 patient)
Peeling (1 patient)
Sources:
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Other AEs: Ataxia, Anorexia...
Other AEs:
Ataxia (3 patients)
Anorexia (4 patients)
Nausea (severe, 2 patients)
Vomiting (3 patients)
Stomatitis (mild, 3 patients)
Diarrhea (2 patients)
Weakness (2 patients)
Hair loss (2 patients)
Loss of eyelashes (1 patient)
Peeling (2 patients)
Peeling (2 patients)
Sources:
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 3
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 3
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3, 1 patient)
Sources:
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 14
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 14
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 9
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 9
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
n = 257
Health Status: unhealthy
Condition: actinic keratoses
Age Group: adult
Sex: M+F
Population Size: 257
Sources:
Disc. AE: Irritation skin...
AEs leading to
discontinuation/dose reduction:
Irritation skin (12%)
Sources:
1250 mg 1 times / 2 days multiple, oral
Dose: 1250 mg, 1 times / 2 days
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / 2 days
Sources:
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: hepatoma
Age Group: adult
Population Size: 7
Sources:
500 mg single, oral
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 6
Sources:
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Other AEs: Anaemia, Angina unstable...
Other AEs:
Anaemia (serious, 2 patients)
Angina unstable (serious, 5 patients)
Arrhythmia (serious, 2 patients)
Arteriosclerosis coronary artery (serious, 1 patient)
Atrial flutter (serious, 3 patients)
Atrial tachycardia (serious, 1 patient)
Atrial thrombosis (serious, 1 patient)
Cardiac disorder (serious, 1 patient)
Cardiac failure congestive (serious, 7 patients)
Cardio-respiratory arrest (serious, 2 patients)
Coronary artery stenosis (serious, 1 patient)
Myocardial ischaemia (serious, 1 patient)
Palpitations (serious, 1 patient)
Pericarditis (serious, 1 patient)
Ventricular tachycardia (serious, 2 patients)
Vertigo (serious, 1 patient)
Vertigo positional (serious, 1 patient)
Disorder vestibular (serious, 1 patient)
Goitre (serious, 1 patient)
Inappropriate antidiuretic hormone secretion (serious, 1 patient)
Abdominal hernia (serious, 1 patient)
Colitis ischaemic (serious, 1 patient)
Gastritis (serious, 2 patients)
Haemorrhoids (serious, 1 patient)
Impaired gastric emptying (serious, 1 patient)
Hernia inguinal (serious, 1 patient)
Intestinal obstruction (serious, 2 patients)
Obstruction gastric (serious, 1 patient)
Oesophageal obstruction (serious, 1 patient)
Pancreatitis (serious, 1 patient)
Vomiting (serious, 1 patient)
Adhesion (serious, 1 patient)
Chest discomfort (serious, 1 patient)
Generalised oedema (serious, 1 patient)
Non-cardiac chest pain (serious, 3 patients)
Cholelithiasis (serious, 2 patients)
Hepatitis alcoholic (serious, 1 patient)
Arthritis infective (serious, 1 patient)
Bacteraemia (serious, 1 patient)
Bronchopneumonia (serious, 1 patient)
Cholecystitis infective (serious, 1 patient)
Clostridium difficile infection (serious, 3 patients)
Cystitis (serious, 1 patient)
Endocarditis (serious, 1 patient)
Incision site cellulitis (serious, 1 patient)
Infection (serious, 2 patients)
Septic shock (serious, 1 patient)
Upper respiratory tract infection (serious, 1 patient)
Urinary tract infection (serious, 6 patients)
Viral infection (serious, 1 patient)
Device toxicity (serious, 1 patient)
Fall (serious, 11 patient)
Hip fracture (serious, 2 patients)
Intentional overdose (serious, 1 patient)
Limb injury (serious, 1 patient)
Lower limb fracture (serious, 1 patient)
Meniscus injury (serious, 2 patients)
Periprosthetic fracture (serious, 1 patient)
Postoperative fever (serious, 1 patient)
Procedural nausea (serious, 1 patient)
Procedural pain (serious, 1 patient)
Radiation oesophagitis (serious, 1 patient)
Road traffic accident (serious, 2 patients)
Traumatic haematoma (serious, 1 patient)
Vascular bypass dysfunction (serious, 1 patient)
Blood glucose increased (serious, 1 patient)
Electrocardiogram abnormal (serious, 1 patient)
Haemoglobin decreased (serious, 1 patient)
International normalised ratio increased (serious, 2 patients)
White blood cell count increased (serious, 1 patient)
Dehydration (serious, 5 patients)
Diabetes mellitus inadequate control (serious, 2 patients)
Failure to thrive (serious, 3 patients)
Hyperglycaemia (serious, 2 patients)
Hyponatraemia (serious, 3 patients)
Iron deficiency (serious, 1 patient)
Arthralgia (serious, 3 patients)
Bursa disorder (serious, 1 patient)
Exostosis (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Osteoarthritis (serious, 10 patients)
Tendonitis (serious, 1 patient)
Basal cell carcinoma (serious, 1 patient)
Benign salivary gland neoplasm (serious, 1 patient)
Brain neoplasm (serious, 2 patients)
Colorectal cancer (serious, 1 patient)
Diffuse large B-cell lymphoma stage IV (serious, 1 patient)
Haemangioma (serious, 1 patient)
Lung neoplasm malignant (serious, 4 patients)
Malignant melanoma (serious, 3 patients)
Metastases to central nervous system (serious, 1 patient)
Metastatic squamous cell carcinoma (serious, 1 patient)
Neuroendocrine carcinoma (serious, 1 patient)
Prostate cancer (serious, 5 patients)
Prostate cancer recurrent (serious, 1 patient)
Renal cancer (serious, 2 patients)
Renal cancer metastatic (serious, 1 patient)
Renal cell carcinoma (serious, 1 patient)
Salivary gland cancer (serious, 1 patient)
Squamous cell carcinoma (serious, 2 patients)
Basilar artery stenosis (serious, 1 patient)
Cognitive disorder (serious, 1 patient)
Dementia (serious, 4 patients)
Epilepsy (serious, 1 patient)
Headache (serious, 1 patient)
Hypoaesthesia (serious, 1 patient)
Parkinson's disease (serious, 2 patients)
Haemorrhage subarachnoid (serious, 1 patient)
Transient ischaemic attack (serious, 4 patients)
Transient ischaemic attack (serious, 4 patients)
Dementia vascular (serious, 1 patient)
Alcohol abuse (serious, 2 patients)
Binge drinking (serious, 1 patient)
Completed suicide (serious, 1 patient)
Confusional state (serious, 1 patient)
Delirium tremens (serious, 1 patient)
Depression (serious, 3 patients)
Mental disorder (serious, 1 patient)
Mental status changes (serious, 2 patients)
Post-traumatic stress disorder (serious, 1 patient)
Suicidal behaviour (serious, 1 patient)
Suicidal ideation (serious, 3 patients)
Hydronephrosis (serious, 2 patients)
Nephropathy (serious, 1 patient)
Renal failure chronic (serious, 1 patient)
Erectile dysfunction (serious, 1 patient)
Prostatic haemorrhage (serious, 1 patient)
Prostatitis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 9 patients)
Dyspnoea (serious, 2 patients)
Dyspnoea exertional (serious, 1 patient)
Haemoptysis (serious, 1 patient)
Pleural effusion (serious, 1 patient)
Pulmonary embolism (serious, 3 patients)
Respiratory failure (serious, 1 patient)
Rash (serious, 1 patient)
Angioplasty (serious, 1 patient)
Cholecystectomy (serious, 1 patient)
Coronary angioplasty (serious, 1 patient)
Elective procedure (serious, 1 patient)
Hip arthroplasty (serious, 1 patient)
Knee arthroplasty (serious, 1 patient)
Medical device removal (serious, 1 patient)
Oesophagogastric fundoplasty (serious, 1 patient)
Parotidectomy (serious, 1 patient)
Wound treatment (serious, 1 patient)
Aortic aneurysm (serious, 2 patients)
Aortic occlusion (serious, 1 patient)
Arterial occlusive disease (serious, 1 patient)
Femoral artery occlusion (serious, 1 patient)
Labile hypertension (serious, 1 patient)
Orthostatic hypotension (serious, 2 patients)
Disorder peripheral vascular (serious, 1 patient)
Lymphadenopathy (below serious, 1 patient)
Vertigo (below serious, 1 patient)
Adrenal mass (below serious, 1 patient)
Eye haemorrhage (below serious, 1 patient)
Eye irritation (below serious, 3 patients)
Eye pain (below serious, 2 patients)
Eye pruritus (below serious, 1 patient)
Eye swelling (below serious, 4 patients)
Photophobia (below serious, 1 patient)
Visual acuity reduced (below serious, 1 patient)
Abdominal pain upper (below serious, 2 patients)
Cheilitis (below serious, 1 patient)
Diarrhoea (below serious, 3 patients)
Diverticulum (below serious, 1 patient)
Dyspepsia (below serious, 1 patient)
Gastrooesophageal reflux disease (below serious, 1 patient)
Gingival pain (below serious, 1 patient)
Nausea (below serious, 5 patients)
Fatigue (below serious, 3 patients)
Feeling of body temperature change (below serious, 1 patient)
Hernia (below serious, 1 patient)
Local swelling (below serious, 1 patient)
Malaise (below serious, 1 patient)
Pain (below serious, 11 patient)
Syringe issue (below serious, 1 patient)
Temperature intolerance (below serious, 1 patient)
Tenderness (below serious, 2 patients)
Vessel puncture site haematoma (below serious, 1 patient)
Hypersensitivity (below serious, 1 patient)
Seasonal allergy (below serious, 1 patient)
Bronchitis (below serious, 4 patients)
Cellulitis (below serious, 1 patient)
Folliculitis (below serious, 1 patient)
Fungal infection (below serious, 1 patient)
Herpes zoster (below serious, 2 patients)
Infection (below serious, 2 patients)
Influenza (below serious, 1 patient)
Nasopharyngitis (below serious, 5 patients)
Oral herpes (below serious, 1 patient)
Pneumonia (below serious, 2 patients)
Accidental exposure to product (below serious, 1 patient)
Arthropod sting (below serious, 1 patient)
Fall (below serious, 5 patients)
Laceration (below serious, 1 patient)
Muscle rupture (below serious, 1 patient)
Body temperature increased (below serious, 1 patient)
Emergency care examination (below serious, 1 patient)
Gout (below serious, 1 patient)
Arthralgia (below serious, 1 patient)
Back pain (below serious, 3 patients)
Foot deformity (below serious, 1 patient)
Musculoskeletal pain (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Pain in extremity (below serious, 1 patient)
Polymyalgia rheumatica (below serious, 1 patient)
Basal cell carcinoma (below serious, 1 patient)
Haemangioma (below serious, 1 patient)
Transitional cell carcinoma (below serious, 1 patient)
Burning sensation (below serious, 1 patient)
Dizziness (below serious, 4 patients)
Headache (below serious, 5 patients)
Hypoaesthesia (below serious, 2 patients)
Syncope (below serious, 1 patient)
Tunnel vision (below serious, 1 patient)
Abnormal dreams (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Psychotic disorder (below serious, 1 patient)
Sleep disorder (below serious, 22 patients)
Dysuria (below serious, 1 patient)
Haemorrhage urinary tract (below serious, 1 patient)
Pollakiuria (below serious, 1 patient)
Chronic obstructive pulmonary disease (below serious, 1 patient)
Nasal congestion (below serious, 1 patient)
Productive cough (below serious, 1 patient)
Pulmonary mass (below serious, 1 patient)
Rhinorrhoea (below serious, 1 patient)
Sinus disorder (below serious, 1 patient)
Acne (below serious, 5 patients)
Blister (below serious, 2 patients)
Blood blister (below serious, 1 patient)
Decubitus ulcer (below serious, 1 patient)
Dermatitis (below serious, 447 patients)
Dermatitis allergic (below serious, 1 patient)
Hyperhidrosis (below serious, 2 patients)
Photosensitivity reaction (below serious, 5 patients)
Post inflammatory pigmentation change (below serious, 1 patient)
Scab (below serious, 1 patient)
Seborrhoea (below serious, 1 patient)
Dermatitis seborrhoeic (below serious, 2 patients)
Skin discomfort (below serious, 1 patient)
Skin haemorrhage (below serious, 3 patients)
Skin tightness (below serious, 1 patient)
Skin ulcer (below serious, 1 patient)
Urticaria (below serious, 1 patient)
Oral surgery (below serious, 1 patient)
Wound drainage (below serious, 1 patient)
Haemorrhage (below serious, 7 patients)
Temporal arteritis (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hair loss 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Peeling 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Weakness 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Vomiting 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Anorexia 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Diarrhea 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Ataxia grade 3, 4 patients
DLT, Disc. AE
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Stomatitis severe, 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Nausea severe, 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Loss of eyelashes 1 patient
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Diarrhea 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Hair loss 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Weakness 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Ataxia 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Vomiting 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Anorexia 4 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Stomatitis mild, 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Nausea severe, 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
n = 8
Health Status: unhealthy
Condition: Advanced Pancreatic Cancer| Colorectal Cancer
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Population Size: 8
Sources:
Diarrhea grade 3, 1 patient
DLT
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 3
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 3
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 14
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 14
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
n = 9
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Population Size: 9
Sources:
Irritation skin 12%
Disc. AE
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
n = 257
Health Status: unhealthy
Condition: actinic keratoses
Age Group: adult
Sex: M+F
Population Size: 257
Sources:
Abnormal dreams below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Accidental exposure to product below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Adrenal mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Anxiety below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arthralgia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arthropod sting below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Basal cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Blood blister below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Body temperature increased below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Burning sensation below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cellulitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cheilitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Chronic obstructive pulmonary disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Decubitus ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dermatitis allergic below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Diverticulum below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dyspepsia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dysuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Emergency care examination below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Eye haemorrhage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Eye pruritus below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Feeling of body temperature change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Folliculitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Foot deformity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Fungal infection below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Gastrooesophageal reflux disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Gingival pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Gout below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemangioma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemorrhage urinary tract below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hernia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hypersensitivity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Influenza below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Laceration below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Local swelling below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Lymphadenopathy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Malaise below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Muscle rupture below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Musculoskeletal pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Nasal congestion below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Neck pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Oral herpes below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Oral surgery below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pain in extremity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Photophobia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pollakiuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Polymyalgia rheumatica below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Post inflammatory pigmentation change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Productive cough below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Psychotic disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pulmonary mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Rhinorrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Scab below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Seasonal allergy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Seborrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Sinus disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Skin discomfort below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Skin tightness below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Skin ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Syncope below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Syringe issue below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Temperature intolerance below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Temporal arteritis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Transitional cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Tunnel vision below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Urticaria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vertigo below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vessel puncture site haematoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Visual acuity reduced below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Wound drainage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pain below serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Abdominal pain upper below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Blister below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dermatitis seborrhoeic below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Eye pain below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Herpes zoster below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hyperhidrosis below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hypoaesthesia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Infection below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pneumonia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Tenderness below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Sleep disorder below serious, 22 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Back pain below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Diarrhoea below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Eye irritation below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Fatigue below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Skin haemorrhage below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Bronchitis below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dizziness below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Eye swelling below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dermatitis below serious, 447 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Acne below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Fall below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Headache below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Nasopharyngitis below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Nausea below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Photosensitivity reaction below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemorrhage below serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Abdominal hernia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Adhesion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Aortic occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arterial occlusive disease serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arteriosclerosis coronary artery serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arthritis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Atrial tachycardia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Atrial thrombosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Bacteraemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Basal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Basilar artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Benign salivary gland neoplasm serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Binge drinking serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Blood glucose increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Bronchopneumonia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Bursa disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cardiac disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Chest discomfort serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cholecystectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cholecystitis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cognitive disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Colitis ischaemic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Colorectal cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Completed suicide serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Confusional state serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Coronary angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Coronary artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cystitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Delirium tremens serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dementia vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Device toxicity serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Diffuse large B-cell lymphoma stage IV serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Disorder peripheral vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Disorder vestibular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dyspnoea exertional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Elective procedure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Electrocardiogram abnormal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Endocarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Epilepsy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Erectile dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Exostosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Femoral artery occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Generalised oedema serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Goitre serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemangioma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemoglobin decreased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemoptysis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemorrhage subarachnoid serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Haemorrhoids serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Headache serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hepatitis alcoholic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hernia inguinal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hip arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hypoaesthesia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Impaired gastric emptying serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Inappropriate antidiuretic hormone secretion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Incision site cellulitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Intentional overdose serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Iron deficiency serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Knee arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Labile hypertension serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Limb injury serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Lower limb fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Medical device removal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Mental disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Metastases to central nervous system serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Metastatic squamous cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Muscular weakness serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Myocardial ischaemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Nephropathy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Neuroendocrine carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Obstruction gastric serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Oesophageal obstruction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Oesophagogastric fundoplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Palpitations serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pancreatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Parotidectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pericarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Periprosthetic fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pleural effusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Post-traumatic stress disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Postoperative fever serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Procedural nausea serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Procedural pain serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Prostate cancer recurrent serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Prostatic haemorrhage serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Prostatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Radiation oesophagitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Rash serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Renal cancer metastatic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Renal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Renal failure chronic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Respiratory failure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Salivary gland cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Septic shock serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Suicidal behaviour serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Tendonitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Traumatic haematoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Upper respiratory tract infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vascular bypass dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vertigo positional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vertigo serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Viral infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Vomiting serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
White blood cell count increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Wound treatment serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Osteoarthritis serious, 10 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Fall serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Alcohol abuse serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Anaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Aortic aneurysm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arrhythmia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Brain neoplasm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cardio-respiratory arrest serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cholelithiasis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Diabetes mellitus inadequate control serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dyspnoea serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Gastritis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hip fracture serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hydronephrosis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hyperglycaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Infection serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
International normalised ratio increased serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Intestinal obstruction serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Meniscus injury serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Mental status changes serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Orthostatic hypotension serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Parkinson's disease serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Renal cancer serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Road traffic accident serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Squamous cell carcinoma serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Ventricular tachycardia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Arthralgia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Atrial flutter serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Clostridium difficile infection serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Depression serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Failure to thrive serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Hyponatraemia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Malignant melanoma serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Non-cardiac chest pain serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Pulmonary embolism serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Suicidal ideation serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dementia serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Lung neoplasm malignant serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Angina unstable serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Dehydration serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Prostate cancer serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Urinary tract infection serious, 6 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Cardiac failure congestive serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Chronic obstructive pulmonary disease serious, 9 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
n = 468
Health Status: unhealthy
Condition: Keratinocyte carcinoma
Population Size: 468
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
5-Fluorouracil-induced Raynaud's phenomenon.
1998 Nov
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
1999 Mar
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
1999 Mar 11
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
2000 Dec 15
Continuous intra-arterial 5-FU chemotherapy in a patient with a repeated recurrence of rectal cancer: report of a case.
2000 Jun
Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment.
2001 Feb
Analysis of uracil DNA glycosylase in human colorectal cancer.
2001 Feb
Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer.
2001 Feb
Reconstitution of liver mass via cellular hypertrophy in the rat.
2001 Feb
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
2001 Feb
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
2001 Feb 1
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy.
2001 Feb 1
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
2001 Feb 1
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
2001 Feb 1
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
2001 Feb 15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man.
2001 Jan
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
2001 Jan
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
2001 Jan
Rapidly progressive glomerulonephritis and carcinoma of the hypopharynx.
2001 Jan
Crystallization and preliminary X-ray study of pig liver dihydropyrimidine dehydrogenase.
2001 Jan
Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: a mathematical construct.
2001 Jan
Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
2001 Jan
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.
2001 Jan
Bystander effect in uracil phosphoribosyltransferase/5-fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication.
2001 Jan
Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
2001 Jan 1
Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.
2001 Jan 1
Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth.
2001 Jan 15
Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT).
2001 Jan-Feb
Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: a phase-II study.
2001 Jan-Feb
The significance of thymidine phosphorylase expression in colorectal cancer.
2001 Jan-Feb
Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study.
2001 Jan-Feb
Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy.
2001 Jan-Feb
Therapeutic approaches to metastasis confined to the liver.
2001 Mar
Adjuvant chemotherapy for colon cancer.
2001 Mar
Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.
2001 Mar 1
Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
2001 Mar-Apr
Uracil salvage pathway in PC12 cells.
2001 Nov 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Fluorouracil is recommended for administration either as an intravenous bolus or as an intravenous infusion, but may also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
Recommended Dosage for Adenocarcinoma of the Colon and Rectum: The recommended dose of fluorouracil, administered in an infusional regimen in combination with leucovorin alone, or in combination with leucovorin and oxaliplatin or irinotecan, is 400 mg/m2 by intravenous bolus on Day 1, followed by 2400 mg/m2 to 3000 mg/m2 intravenously as a continuous infusion over 46 hours every two weeks. The recommended dose of fluorouracil, if administered in a bolus dosing regimen in combination with leucovorin, is 500 mg/m2 by intravenous bolus on Days 1, 8, 15, 22, 29, and 36 in 8-week cycles.
Route of Administration: Intravenous
Fluorouracil treatment (0.4uM) inhibited LXA4 secretion in colorectal cancer RKO cells
Name Type Language
FLUOROURACIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
2,4(1H,3H)-PYRIMIDINEDIONE, 5-FLUORO-
Systematic Name English
ADRUCIL
Brand Name English
FLUOROURACILUM [WHO-IP LATIN]
Common Name English
5-FU
Code English
PHTHORURACIL
Common Name English
5-FLUOROURACIL [IARC]
Common Name English
EMTRICITABINE IMPURITY F [WHO-IP]
Common Name English
QUEROPLEX
Common Name English
EFUDEX
Brand Name English
5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE [WHO-IP]
Systematic Name English
5-FLUORURACIL
Common Name English
FLUOROURACIL [ORANGE BOOK]
Common Name English
FLUOROURACIL [EP MONOGRAPH]
Common Name English
5 FU
Code English
CARAC
Brand Name English
TOLAK
Systematic Name English
RO-29757
Code English
FLUOROURICIL
Common Name English
FLUOROURACIL [MI]
Common Name English
RO-2-9757
Code English
FLUOROURACIL [USP-RS]
Common Name English
5-FLUOROURACIL
WHO-IP  
Systematic Name English
FLUOROURACIL [VANDF]
Common Name English
5 FLUOROURACIL
Systematic Name English
FLUOROURACIL [WHO-DD]
Common Name English
FLUOROURACIL [USAN]
Common Name English
FLUCYTOSINE IMPURITY A [EP]
Common Name English
FLUCYTOSINE IMPURITY A [WHO-IP]
Common Name English
FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [JAN]
Common Name English
NSC-19893
Code English
RO 2-9757
Code English
FLUOROURACIL [HSDB]
Common Name English
5-FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [MART.]
Common Name English
5-FLUORO-URACIL
Systematic Name English
FLUOROURACIL [USP MONOGRAPH]
Common Name English
FLUOROURACIL [INN]
Common Name English
FLUOROPLEX
Brand Name English
Classification Tree Code System Code
LIVERTOX 423
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ATC L01BC02
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
IARC 5-Fluorouracil
FDA ORPHAN DRUG 40589
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ATC L01BC52
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 42289
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-VATC QL01BC02
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NDF-RT N0000000233
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NCI_THESAURUS C2021
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-VATC QL01BC52
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
EU-Orphan Drug EU/3/00/004
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 32088
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NDF-RT N0000175595
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 131799
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
Code System Code Type Description
MERCK INDEX
M5483
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY Merck Index
FDA UNII
U3P01618RT
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
WIKIPEDIA
FLUOROURACIL
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-085-6
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUOROURACIL
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Fluorouracil should be kept in a tightly closed container, protected from light. Additional information: Fluorouracil melts at about 282?C with decomposition. CAUTION: Fluorouracil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Fluorouracil contains not less than 98.5% and not more than 101.0% of C4H3FN2O2, calculated with reference to the dried substance.
MESH
D005472
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
DRUG CENTRAL
26
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
ChEMBL
CHEMBL185
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
NCI_THESAURUS
C505
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
EVMPD
SUB07721MIG
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
PUBCHEM
3385
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
EPA CompTox
51-21-8
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
USP_CATALOG
1279000
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY USP-RS
HSDB
3228
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
IUPHAR
4789
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
RXCUI
4492
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY RxNorm
LACTMED
Fluorouracil
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
CAS
51-21-8
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
INN
1421
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
DRUG BANK
DB00544
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY